Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigious | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
accomplishment, Andrzejewski, Appendix, arrangement, asExhibit, Brouillette, category, chart, Confidential, Deavenport, Delaware, description, dividend, earned, Earnest, Elizabeth, EMIA, Exhibit, foster, Frederick, functional, Greetham, hereto, Incentive, infection, Irvine, Jr, licensee, lifted, Lupin, Maryland, Nonqualified, opportunity, Pfeffer, Philip, predetermined, Proxy, Ratified, regain, salary, Sicor, Stephen, stretch, tailored, Teva, unfunded, voluntarily, Wisconsin
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 EX-10.1 Offer Letter to Joseph Squicciarino Dated May 6, 2005
- 10.2 EX-10.2 Offer Letter to Eric J. Bruce Dated May 19, 2005
- 10.3 EX-10.3 Retirement and Consulting Agreement, Dated April 5, 2005 by and Between King Pharmaceuticals, Inc. and James R. Lattanzi
- 10.4 EX-10.4 2005 Executive Management Incentive Award
- 10.6 EX-10.6 Compensation Policy for Non-employee Directors
- 10.7 EX-10.7 Salary Amendments to Employment Arrangements with Certain Executive Officers
- 10.8 EX-10.8 King Pharmaceuticals, Inc. Executive Deferred Compensation Plan
- 31.1 EX-31.1 Section 302 Certification of the CEO
- 31.2 EX-31.2 Section 302 Certification of the CFO
- 32.1 EX-32.1 Section 906 Certification of the CEO
- 32.2 EX-32.2 Section 906 Certification of the CFO
Related press release
King Pharmaceuticals similar filings
External links